FDA Has Not Approved Testosterone for Women Despite Rising Off-Label Use

That rising curiosity targets testosterone as a potential treatment for low female libido, a condition affecting women of all ages.

Despite years of research suggesting the hormone can boost sexual function and desire among postmenopausal women, the U.S. Food and Drug Administration has yet to approve a female testosterone product, Science News reported.

Approval status differs internationally, as female testosterone products are already approved in countries including the United Kingdom and Australia. Meanwhile, American women seeking these potential benefits currently must look for them off-label.

Interest in the United States has climbed sharply in recent years. Statistics highlighted by Science News show that prescriptions given to U.S. women for any reason climbed from 0.4 per 1,000 females in 2018 to 1.8 per 1,000 females by 2026.

Women turning to testosterone therapy running into unexpected prescription delays — FOX 13 Seattle

Testosterone Studied for Low Sexual Desire in Women

  • Testosterone is an androgen hormone that researchers are studying to help treat low sexual desire in women, though it lacks U.S. regulatory approval for this specific use.
  • Clinical data suggest the hormone works by interacting with the central nervous system to make the brain more receptive to sexual stimuli while enhancing physical blood flow.
  • Because of high public expectations, clinical trials have often struggled with strong placebo effects, where inactive treatments mimic real results.

Although limited scientific literature has examined how testosterone impacts libido among premenopausal women, a 2026 literature review published in The Journal of Sexual Medicine—co-authored by Yih—indicates that early findings in this demographic are also encouraging. “I have seen it change people’s lives,” Yih told Science News.

The biological mechanism appears twofold. The hormone seems to make the female brain more receptive to sexual stimuli, as detailed in research published in The Lancet, while also promoting physical effects that enhance sexual pleasure, such as increased blood flow to the genitals documented in studies highlighted by Springer.

Accelerating Testosterone Use in Women Brings New Health Concerns — UC San Diego School of Medicine

Regulatory paths in the United States have faced historical hurdles. Back in 2004, a panel of FDA advisors voted unanimously against the greenlight for a female testosterone patch, pointing out insufficient safety documentation.

Later, in 2011, a pair of Phase III trials found that testosterone therapy didn’t significantly outperform a placebo, failing to meet the benchmark the FDA looks for when deciding whether to approve a new drug based on data similar to findings published in the New England Journal of Medicine.

Women make testosterone too—so why is prescribing it still so controversial? — Manhattan Surgical Care

That outcome did not mean the treatment failed, according to Tami Rowen, an ob-gyn at UC San Francisco. Instead, enthusiasm surrounding the hormone appeared so intense that volunteers entered the trials anticipating extraordinary results, which caused even those receiving dummy treatments to note improvements.

The treatment was a “victim of its own success,” Rowen told Science News.

Testosterone Therapy for Menopausal Women – The FDA Approval Gap — IntimMedicine Specialists

Regulatory discussions have begun to shift again. In September, the FDA held a public meeting on testosterone use among menopausal women, “with the goal of informing future research and potential drug development in this area,” Kaveeta Vasisht, the FDA’s associate commissioner for women’s health, told Science News.

Treatment Category Regulatory Status (U.S.) Target Demographic
Testosterone Therapy Off-label use only (No FDA-approved female product) Postmenopausal and premenopausal women
Addyi (Flibanserin) FDA-approved (Expanded in 2025 to postmenopausal women under 65) Premenopausal and postmenopausal women
Vyleesi (Bremelanotide) FDA-approved (Hit shelves in 2019) Premenopausal women

Women seeking a libido boost do have non-hormonal options currently available on the market. In 2015, the FDA approved Addyi, the first treatment for low libido in premenopausal women, which raises levels of neurotransmitters that promote sexual desire while tamping down those that block it.

A competitor, Vyleesi, hit shelves in 2019. Last year, regulators expanded Addyi’s use to postmenopausal women younger than 65.

Guidelines for managing diminished sexual desire in women were published in 2025 within Sexual Medicine Reviews by a global consortium of specialists, which featured Rowen as a contributor.

Rowen currently has her eye on in-development products including Lybrido, a drug slated to enter a Phase III clinical trial in Europe that aims to rev sex drive in the brain and enhance physical arousal.

Long-Term Risks of Breast Cancer and Heart Disease Uncertain

Yih said that outstanding questions remain on how, if at all, long-term use affects the risk of conditions such as breast cancer and heart disease.

Science News has reported on scientific developments since 1922, when the Society for Science & the Public launched it as Science News Letter; the magazine adopted its current name in 1966. Published by a nonprofit founded by E. W. Scripps in 1920, it covers all sciences for a general audience and shifted from weekly to monthly frequency in 2025.

The demand for new treatments remains high as researchers continue to evaluate clinical data. “Women deserve better than placebo,” Rowen told Science News.

References

  • The Journal of Sexual Medicine – 2026 research review on testosterone and female sexual function
  • The Lancet Diabetes & Endocrinology – Research on neurological mechanisms of testosterone
  • New England Journal of Medicine – Clinical trial methodology and placebo response evaluations
  • Sexual Medicine Reviews – 2025 international expert recommendations for treating low female libido
Photo of author

Health Desk

Health Desk at Archyde.

Joe Napier tips Kingofthefrontier for the 1:15 at Haydock

Man Utd Rival Liverpool for Scalvini; McTominay Return Eyed